India Drug Authorities To Review Suspension Of Three Popular Drugs
This article was originally published in PharmAsia News
Executive Summary
India drug regulators plan a review of the controversial decision to suspend the manufacturing and marketing of Takeda’s off-patent Actos (pioglitazone), Lundbeck’s Deanxit (flupentixol/melitracen), and Analgin (metamizole) in response to reports of adverse effects.